Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in ...
ATHE Stock | USD 3.34 0.06 1.83% |
About 54% of Alterity Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Alterity Therapeutics suggests that some traders are interested. The current market sentiment, together with Alterity Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Alterity Therapeutics stock news signals to limit their universe of possible portfolio assets.
Alterity |
ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders Topline Data Expected in Early 2025
Read at gurufocus.com
Alterity Therapeutics Fundamental Analysis
We analyze Alterity Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Alterity Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Alterity Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alterity Therapeutics stock to make a market-neutral strategy. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics with similar companies.
Peers
Alterity Therapeutics Related Equities
RNAZ | Transcode Therapeutics | 57.59 | ||||
ATXI | Avenue Therapeutics | 6.36 | ||||
MNPR | Monopar Therapeutics | 6.28 | ||||
PMVP | Pmv Pharmaceuticals | 5.30 | ||||
ADIL | Adial Pharmaceuticals | 2.08 | ||||
ARTL | Artelo Biosciences | 1.69 | ||||
ANTX | AN2 Therapeutics | 0.79 | ||||
TARA | Protara Therapeutics | 1.47 | ||||
SRZN | Surrozen | 1.54 | ||||
ANEB | Anebulo Pharmaceuticals | 1.86 | ||||
RVPH | Reviva Pharmaceuticals | 2.58 | ||||
HCWB | HCW Biologics | 2.86 | ||||
ADTX | Aditxt | 8.33 | ||||
NBY | NovaBay Pharmaceuticals | 12.35 | ||||
QNRX | Quoin Pharmaceuticals | 30.51 |
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |